Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

2.050 -0.070 (-3.30%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

October 15, 2026

First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial...

From Xenetic Biosciences, Inc.

Via ACCESS Newswire

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

September 16, 2026

Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune...

From Xenetic Biosciences, Inc.

Via ACCESS Newswire

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

August 07, 2026

From Xenetic Biosciences, Inc.

Via ACCESS Newswire

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

June 04, 2026

Via ACCESS Newswire

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

June 01, 2026

Via ACCESS Newswire

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

May 13, 2026

Via ACCESS Newswire

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

April 22, 2026

Via ACCESS Newswire

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

March 13, 2026

Via ACCESS Newswire

Why Did UPB Stock Pop 20% In Pre-Market Today? ↗

February 11, 2026

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Via Stocktwits

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

December 11, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 19, 2025

Via Benzinga

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

November 19, 2025

Via ACCESS Newswire

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

November 13, 2025

Via ACCESS Newswire

Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges ↗

October 10, 2025

Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

October 10, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 10, 2025

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

October 10, 2025

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

October 10, 2025

Via ACCESS Newswire

4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings ↗

October 09, 2025

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs....

Via Benzinga

Which stocks are moving before the opening bell on Thursday? ↗

October 09, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 09, 2025

Via Benzinga

MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside

October 08, 2025

Via AB Newswire

Topics Artificial Intelligence Intellectual Property

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 08, 2025

Via Benzinga

Nasdaq Gains 150 Points; US Mortgage Applications Decline ↗

October 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 08, 2025

Via Benzinga

Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

October 08, 2025

Via Benzinga

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

August 13, 2025

Via ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

July 30, 2025

Via ACCESS Newswire

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

July 23, 2025

Via ACCESS Newswire

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic

July 08, 2025

Via ACCESS Newswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.